Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.

Register for Details

For more details on financing and valuation for Freenome, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Freenome

To invest in Freenome pre-IPO

Can you invest in Freenome pre-IPO?

Freenome is a privately held company and is not publicly traded, therefore investing in Freenome pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Freenome before it goes public?

You can seek to sell your shares in Freenome while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Freenome shares?

To determine the value of your Freenome shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Freenome shares. You can also learn more about how to sell your private shares before getting started.

Is Freenome a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Freenome potential IPO

Will Freenome go IPO?

Freenome has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Freenome’s IPO price?

The Freenome IPO price does not exist at this time, as Freenome is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Freenome register for Forge Markets, today.

When was Freenome founded?

Freenome was founded in 2014.

What is Freenome funding to date?

Freenome has raised $2.46B to date.

Who are Freenome’s major investors?

Colorectal Cancer Alliance
Anne Wojcicki
Ark Investments
Asset Management Ventures
Sands Capital
Ridgeback Capital
Cormorant Asset Management
T. Rowe Price Associates
Startx (Stanford-Startx Fund)
Kaiser Permanente
Data Collective
Rock Springs Capital
Bain Capital
Arrowmark Partners
Janus Henderson Investors
Founders Fund
Byers Capital
Ecor1 Capital
Novartis
Innovation Endeavors
Catalio Capital Management
Soleus Capital
Charles River Ventures
Logos Capital
Ra Capital Management
Agent Capital
Pura Vida Investments
Dcvc
Soleus Capital Management
Kaiser Permanente Ventures
Gv
Eventide Asset Management Llc
Perceptive Advisors
Ridgeback Capital Management
K50 Ventures
Ame Cloud Ventures
Cormorant Capital
Squarepoint Capital
Intermountain Ventures
Fidelity
Brightedge
Longevity Vision Fund
Farallon Capital Management
Bain Capital Life Sciences
S32
T. Rowe Price
Andreessen Horowitz
Roche
Brightedge Ventures
Polaris Partners
Artis Ventures
Quest Diagnostics
Roche Venture Fund
Data Collective Venture Capital
S28 Capital
Verily Life Sciences
Fidelity Investments
American Cancer Society�S Brightedge Ventures
Undisclosed Investors
Gv (Formerly Google Ventures)
Allen & Company
Crv
Spectrum 28
Third Kind Venture Capital
Section 32

Freenome Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
02/15/2024 Series F $254MM $xx.xx $2.17B Andreessen Horowitz, Ark Investments, Arrowmark Partners, Artis Ventures, Bain Capital Life Sciences, Brightedge Ventures, Cormorant Capital, Dcvc, Eventide Asset Management Llc, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, Ra Capital Management, Roche, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates
Price per Share
$xx.xx
Shares Outstanding
34,330,819
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Ark Investments, Arrowmark Partners, Artis Ventures, Bain Capital Life Sciences, Brightedge Ventures, Cormorant Capital, Dcvc, Eventide Asset Management Llc, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, Ra Capital Management, Roche, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates
01/11/2022 Series E $290MM $xx.xx $2.74B Roche
Price per Share
$xx.xx
Shares Outstanding
24,856,432
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Roche
12/07/2021 Series D $300MM $xx.xx $1.43B Andreessen Horowitz, Artis Ventures, Bain Capital, Brightedge Ventures, Catalio Capital Management, Cormorant Capital, Dcvc, Farallon Capital Management, Fidelity, Gv, Janus Henderson Investors, Kaiser Permanente, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, T. Rowe Price Associates
Price per Share
$xx.xx
Shares Outstanding
39,775,664
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Artis Ventures, Bain Capital, Brightedge Ventures, Catalio Capital Management, Cormorant Capital, Dcvc, Farallon Capital Management, Fidelity, Gv, Janus Henderson Investors, Kaiser Permanente, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, T. Rowe Price Associates
08/26/2020 Series C $270MM $xx.xx $927.08MM American Cancer Society�S Brightedge Ventures, Andreessen Horowitz, Bain Capital, Catalio Capital Management, Colorectal Cancer Alliance, Cormorant Asset Management, Dcvc, Ecor1 Capital, Farallon Capital Management, Fidelity, Gv (Formerly Google Ventures), Janus Henderson Investors, Kaiser Permanente Ventures, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital, T. Rowe Price Associates
Price per Share
$xx.xx
Shares Outstanding
40,826,799
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
American Cancer Society�S Brightedge Ventures, Andreessen Horowitz, Bain Capital, Catalio Capital Management, Colorectal Cancer Alliance, Cormorant Asset Management, Dcvc, Ecor1 Capital, Farallon Capital Management, Fidelity, Gv (Formerly Google Ventures), Janus Henderson Investors, Kaiser Permanente Ventures, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital, T. Rowe Price Associates
07/24/2019 Series B $165MM $xx.xx $464.3MM Andreessen Horowitz, Brightedge Ventures, Data Collective Venture Capital, Gv, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Section 32, T. Rowe Price Associates, Verily Life Sciences
Price per Share
$xx.xx
Shares Outstanding
36,207,457
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Brightedge Ventures, Data Collective Venture Capital, Gv, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Section 32, T. Rowe Price Associates, Verily Life Sciences
08/28/2017 Series A $69.62MM $xx.xx $196.16MM Allen & Company, Ame Cloud Ventures, Anne Wojcicki, Asset Management Ventures, Charles River Ventures, Data Collective, Founders Fund, Gv, Innovation Endeavors, Polaris Partners, Section 32, Spectrum 28
Price per Share
$xx.xx
Shares Outstanding
22,660,320
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Ame Cloud Ventures, Anne Wojcicki, Asset Management Ventures, Charles River Ventures, Data Collective, Founders Fund, Gv, Innovation Endeavors, Polaris Partners, Section 32, Spectrum 28
06/19/2016 Series Seed-2 $5.55MM $xx.xx $25.34MM Andreessen Horowitz, Data Collective, Founders Fund, Third Kind Venture Capital
Price per Share
$xx.xx
Shares Outstanding
9,092,395
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Data Collective, Founders Fund, Third Kind Venture Capital
05/06/2016 Series Seed-1 $800,016.00 $xx.xx $2.67MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
3,360,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Updated on: Dec 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.